drugset / Trial / NCT00620854

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

NCT00620854

Phase 2 Completed 24 enrolled Tarsa Therapeutics, Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).

Timeline

Start
2008-02
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator salmon calcitonin Unknown 0.15 mg Oral
Comparator salmon calcitonin Unknown 0.2 mg Oral
Comparator salmon calcitonin Unknown 200 iu Oral

Indications